Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 10:01:37 Source:businessViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Russia begins nuclear drills in an apparent warning to West over Ukraine
Next:EU seals a deal on using profits from frozen Russian assets to help arm Ukraine
You may also like
- Australia's deputy prime minister pledges support to Solomon Islands during visit to Honiara
- Former world champion runner Jeruto faces doping case hearing in June ahead of Paris Olympics
- US court rejects a request by tribes to block $10B energy transmission project in Arizona
- MAN UNITED CONFIDENTIAL: How more than TEN stars could be exit
- Georgia QB Jaden Rashada sues Florida coach, others over failed $14M NIL deal
- The United States and China are expected to win the most medals at the Paris Olympics
- A storm dumps record rain across the desert nation of UAE and floods the Dubai airport
- Lynn earns his first win in second stint with Cards, who beat A's before season
- Biden to release 1 million barrels of gasoline in bid to lower prices at pump